GlobeNewswire·Mar 26, 2026, 8:30 AM ET

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

RenovoRx reports the TIGeR-PaC Phase III clinical trial has surpassed 100 randomized patients with enrollment completion expected in the first half of 2026.
Final data for the TIGeR-PaC trial is anticipated in 2027, following a protocol requiring 114 randomized patients & 86 death events.
As of March 24, 2026, 104 patients have been randomized & 72 events have occurred, with both prior interim analyses recommending trial continuation.
Select cancer centers participating in the trial are now using the RenovoCath device as a stand-alone unit to deliver the TAMP™ therapy platform for solid tumors.
The investigational product candidate IAG (intra-arterial gemcitabine via RenovoCath) is under FDA review via a 21 CFR 312 pathway & received Orphan Drug Designation for pancreatic & bile duct cancers.
RenovoRx generated approximately $900,000 in revenue from RenovoCath sales during the first nine months of 2025 & has secured repeat orders from National Cancer Institute-designated centers.
The company is actively commercializing RenovoCath as a stand-alone device while pursuing additional revenue strategies through direct sales or partnerships.